PHARMACEUTICAL IP

  • Our Offering
    • Due diligence
    • Established pharma
    • Evolve AI
    • Fractional IP counsel
    • International IP counsel
    • Investors
    • Oppositions and appeals
    • Start-ups
  • Fractional IP counsel
  • Evolve AI
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapy
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Due diligence
    • Established pharma
    • Evolve AI
    • Fractional IP counsel
    • International IP counsel
    • Investors
    • Oppositions and appeals
    • Start-ups
  • Fractional IP counsel
  • Evolve AI
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapy
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Evolve AI
  • Evolve Insights
  • Fractional IP counsel
  • Join us
  • Our offering
  • Our team
  • Sectors
  • Evolve AI
  • Evolve Insights
  • Fractional IP counsel
  • Join us
  • Our offering
  • Our team
  • Sectors

IP Stars: Evolve recognised in 2026 Publication

  • Sector: Patent law
  • 13th September 2026
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image

We are delighted to announce that Evolve IP has been recognised in the 2026 IP STARS rankings. This distinction reflects our team’s ongoing dedication to exceptional intellectual property support, featuring key individual accolades for our patent attorneys.

Steven Gurney has been recognised as a Patent Star. This specific ranking is awarded to senior practitioners who demonstrate proven excellence in high-stakes patent strategy, prosecution, and litigation. Steven is highly commended for his “incredible technical expertise in life sciences” combined with a “commercial and pragmatic approach”. He is further praised by peers and clients for his “technical excellence, responsiveness, creativity and future-focussed” mindset.

Rose Hughes has been named a Notable Practitioner. Highlighting her exceptional work and strategic insight, Rose is praised for her “insightful understanding of European Patent Law” and her ability to “apply it at the cutting edge”.

Congratulations to Steven and Rose for these well-deserved recognitions, and a sincere thank you to our clients and peers whose continued trust and valued feedback have allowed us to achieve this ranking.

Related insights...

Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image

Franklin: AI-powered publication review for pharma

  • 23rd October 2026
Publication screening is a time sink for pharma patent attorneys. Franklin quickly finds the undisclosed inventions in a new publication submission.
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

Lack of clarity by the backdoor: An ambiguity “may simply result in a broader interpretation” (T 0977/25)

  • 4th October 2026
In T 0977/25, a Board of Appeal found that the word “it” in an amended method claim for an e-cigarette cartridge was ambiguous.
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image

Albert – Construe: defining your claims before they are defined for you.

  • 25th September 2026
Albert – Construe is the latest addition to Evolve’s proprietary AI toolkit.  It construes a set of claims, sets out with supporting evidence what each unclear term means, highlights any inconsistencies caused by other disclosures within an application, and flags where amendments may have changed the scope of a claim term.
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

Evolve Intellectual Property ranked in IAM Patent 1000

  • 13th September 2026
We are proud to announce that Evolve IP has been ranked in the 2026 publication of the IAM Patent 1000: United Kingdom – England and Wales. This year’s guide highlights our deep technical expertise in life sciences and our practical, strategic business focus. Congratulations to our patent attorneys, Steven Gurney who is ranked Silver and Rose Hughes who is…
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

Evolve Intellectual Property recognised in Legal500 rankings

  • 13th September 2026
Evolve Intellectual property is delighted to once again be recognised in the 2026 edition of Legal 500 for our growing specialised life science IP Practice in Cambridge, UK. The publication highlights Steven Gurney (founder and European, UK, and Australian patent attorney) for his work protecting key biopharmaceutical assets and for his focus on complex prosecution…
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

G1/25: What are the consequences?

  • 12th September 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

AI in the patent industry: Beware the MCP Trojan horse

  • 11th September 2026
As patent attorneys, we should all know by now not to put client confidential information to a non-enterprise version of an LLM. However, as the capabilities of AI tools become more complex, so too does the necessity of understanding what exactly they are doing and where our data goes, beyond the simple prompt.
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

BREAKING: When real doubt hits – G1/25 changes the description adaptation requirement for the worse

  • 4th September 2026
G 1/25, issued today, holds that the description must be adapted only where an “inconsistency” between the claims and description causes non-compliance with another requirement of the EPC.
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)

  • 23rd July 2026
We now have confirmation of a new referral to the EBA on claim interpretation (G1/26). As previously hinted, The Board of Appeal in T 0873/24 has decided to refer questions on the application of G1/24 to the assessment of added matter.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

AI in the patent industry: Bubble trouble and the affordability myth

  • 20th July 2026
Whenever we write about AI, responses have started to move away from talk about hallucination, confidentiality or quality. The new concern is one of economics, i.e. will the whole AI thing just become too expensive and are we putting ourselves at risk by outsourcing to AI.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Subscribe
  • Contact us